Cellebrite DI (NASDAQ:CLBT) Price Target Increased to $15.00 by Analysts at JPMorgan Chase & Co.

Cellebrite DI (NASDAQ:CLBT) had its price objective hoisted by JPMorgan Chase & Co. from $14.00 to $15.00 in a report released on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 8.70% from the stock’s current price.

CLBT has been the topic of a number of other research reports. Needham & Company LLC boosted their price objective on Cellebrite DI from $13.50 to $14.00 and gave the stock a “buy” rating in a research note on Friday, May 24th. Lake Street Capital started coverage on Cellebrite DI in a research note on Friday, April 19th. They issued a “buy” rating and a $13.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $14.20.

Cellebrite DI Stock Performance

Cellebrite DI stock opened at $13.80 on Wednesday. The firm has a market cap of $2.84 billion, a P/E ratio of -23.79, a P/E/G ratio of 1.84 and a beta of 1.50. The business’s fifty day moving average is $12.38 and its two-hundred day moving average is $11.46. Cellebrite DI has a 52 week low of $6.36 and a 52 week high of $14.11.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Thursday, May 23rd. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. The company had revenue of $89.60 million for the quarter, compared to analyst estimates of $85.34 million. Cellebrite DI had a positive return on equity of 417.94% and a negative net margin of 32.57%. The business’s revenue was up 25.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.03 earnings per share. On average, equities research analysts predict that Cellebrite DI will post 0.34 earnings per share for the current year.

Hedge Funds Weigh In On Cellebrite DI

Several large investors have recently made changes to their positions in the company. Parallel Advisors LLC lifted its stake in shares of Cellebrite DI by 75.0% during the fourth quarter. Parallel Advisors LLC now owns 3,500 shares of the company’s stock valued at $30,000 after acquiring an additional 1,500 shares during the period. Quarry LP bought a new stake in Cellebrite DI in the fourth quarter valued at about $36,000. California State Teachers Retirement System increased its holdings in Cellebrite DI by 9.1% in the first quarter. California State Teachers Retirement System now owns 56,953 shares of the company’s stock valued at $631,000 after purchasing an additional 4,734 shares during the last quarter. Lazard Asset Management LLC increased its holdings in Cellebrite DI by 28.7% in the first quarter. Lazard Asset Management LLC now owns 21,697 shares of the company’s stock valued at $240,000 after purchasing an additional 4,842 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado bought a new stake in Cellebrite DI in the second quarter valued at about $71,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.